If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||||||||||||||
JOURNALS | |||||||||||||||||||||
 International Journal of CancerSee Also: Copyright © 2008 Wiley-Liss, Inc., A Wiley Company Published on behalf of Journal Home | Funded Access | News Product Information | Editorial Board | For Authors | Subscribe | Advertise | Contact | Online Submission For AuthorsFor additional tools visit Author Resources - an enhanced suite of online tools for Wiley InterScience journal authors, featuring Article Tracking, E-mail Publication Alerts and Customized Research Tools. Instructions to AuthorsOnline Submission and Peer Review
The International Journal of Cancer (official journal of the International Union Against Cancer—UICC) appears 24 times per year. International Journal of Cancer invites submission of manuscripts under a broad scope of topics relevant to experimental and clinical cancer research and publishes original research articles, mini reviews, forum papers, short reports, and letters to the editor. The article categories within the journal are: carcinogenesis, cancer cell biology, cancer genetics, infectious causes of cancer, tumor immunology, early detection and diagnosis, epidemiology, and cancer therapy. Types of ArticlesResearch ArticlesFull research papers should be as concise as possible, without sacrificing documentation of results. For studies on humans, a clear statement must be provided concerning informed consent, and that the study was conducted after Human Experimentation Review by the relevant committee. Research articles should fit within the categories outlined below and meet the editorial standards stated.The journal is pleased to offer a fast publication track for research articles presenting superior novel findings and for studies of greatest priority ranked against similar submissions. The “Fast Track” articles appear earlier than regular papers. Fast Track papers are chosen specifically by the editors according to their judgment and upon the recommendation of reviewers. Presentation of research articles CarcinogenesisCarcinogenesis includes studies on physical and chemical carcinogens, metabolism, repair of carcinogen-modified DNA, molecular dosimetry, the formation, identification and quantification of carcinogens from exogenous and endogenous sources. Reports on mechanistic investigations are particularly welcome and can include both animal and human studies. The cancer-preventive potential of chemical, physical, or biological reagents also fits into this section.Return to Top Cancer Cell BiologyAnalytical and functional data on tumor cell characterization (in vitro and in vivo) and on tumor-stroma interactions are very welcome. Immunohistochemical studies on tumor specimens should comprise reliable characterization of the immune reaction with proof of antibody specificity and selectivity. These data should be seconded by RNA expression and/or functional studies demonstrating the reliability and relevance of the histochemical findings. Confirmatory findings on additional tumor types, stages, or sites without new functional, diagnostic, or therapeutic implications are not within the scope of the journal.Return to Top Cancer GeneticsGenetic studies leading to the identification of factors and biochemical pathways relevant for the pathomechanism of tumors are particularly welcome. For studies concerning polymorphisms and cancer risk, a clear explanation of the biological hypothesis underlying the investigation, including possible biochemical pathways and functional relevance of genetic polymorphisms should be given. In cases of newly identified alleles, the potential functional relevance must be stated. Studies about new diagnostic tools are also within the scope if they hold promise of broad application. Regarding comprehensive data sets of genetic profiling (microarray) studies, raw data must be in a publicly available database that requires MIAME format (for example, "GEO" or "Array Express") upon submission of a paper. Should expert reviewers of the IJC request access to these primary data, authors need to provide the confidential password that is supplied by the database provider.Return to Top Infectious Causes of CancerContributions to this section should cover novel observations on the role of viral, bacterial, or parasitic infections in human cancers. Mechanistic aspects concerning direct or indirect modes of infectious carcinogens will be of particular interest. Functions of viral oncogenes as well as the discovery of new viruses or other infectious pathogens with growth-stimulating properties for infected cells or tissues will be considered. Indirect modes of carcinogenesis by infections are clearly of interest for the journal. Seroepidemiological and immunological studies related to infectious carcinogens will be considered if they present new data or demonstrate novel links between tumors and infections. The development of vaccines directed against tumor-linked infectious agents and their application is also of substantial interest. We also consider submissions on oncolysis by infectious agents.Return to Top Tumor ImmunologyThis section covers novel findings on the immunological relationship between tumor and host, including all aspects of cellular and humoral immunity directed at tumor and associated stromal cells. Experimental and clinical studies based on in vivo, ex vivo and in vitro analysis will be considered. Particularly welcome are studies on new and improved preventive and therapeutic approaches exploiting immune effector mechanisms, such as vaccines. The potential relevance of newly identified tumor cell-associated T cell epitopes should be validated by functional in vivo studies.Return to Top Early Detection and DiagnosisThis section covers the area of predictive and diagnostic markers from molecular biology studies. We invite papers that explore the development and application of nucleic acid-based, protein-based, serological, and other approaches that identify biomarkers linked to cancer as well as the results of current investigations using other novel molecular probes as diagnostic and prognostic indicators for cancer detection and therapy.Return to Top EpidemiologyStudies in human populations providing evidence that i) agents/exposures/host-factors pose a carcinogenic risk or are protective, ii) attempt to establish their causal role, iii) identify (sub-) populations at greatest risk, and iv) host-environment interactions are welcome. These include molecular cancer epidemiology approaches, in which advanced laboratory methods are integrated. Randomized trials, case-control studies, cohort studies, studies of screening and diagnostic tests and intervention studies will be considered. Each manuscript should clearly state an objective or hypothesis, the design and methods (including the source of patients or participants with inclusion/exclusion criteria).Return to Top Cancer TherapyReports on new advances in cancer therapy in humans are welcome, especially the results of well-designed randomized trials. If the authors are describing the results of a randomized controlled trial, we recommend use of the style guidelines in describing the study population (see JAMA 1996; 276:637-639). If the authors are describing the results of observational studies of therapy, the standards applicable in observational studies in epidemiology should be followed (see above). We do not publish case reports.Mini ReviewsThough these are primarily commissioned by the Editors, exceptionally, proposals will be considered and sent for peer review. Presubmission inquiries describing the proposed articles must be sent before submission. The Editors will then indicate whether the review is of potential interest for the journal. Presentation of Mini ReviewsForumForum papers present interesting and controversial topics in cancer research, hypotheses, methods and applications. They are meant to promote discussion and generate new ideas for further study. Presentation of Forum PapersLetters to the EditorComments on published papers and controversial issues, also including negative data that are of general interest or that contradict commonly accepted concepts or hypotheses, will be considered for publication as Letters to the Editor. In the former case, the Editors may invite letters containing pertinent and interesting observations concerning cancer research in general, reports on new observations or pilot studies that do not justify a full research article, or comments on published papers will be considered for publication. In the latter case, the Editors may invite the authors of the paper being questioned to respond. Both letters may then be published, if found to be of interest to the Editors. Presentation of LettersShort ReportsArticles containing pertinent and interesting observations concerning cancer research in general and reports on new observations or studies that do not warrant publication as a full research article will be considered for the Short Report section. These articles will undergo full peer review. Presentation of Short Reports Special Section PaperThese papers are commissioned by the Editors. Authors of Special Section Papers will be given individual guidance in preparing their manuscripts. PresentationArticles should be written in English (either British or American spelling).Research ArticlesResearch articles should be divided into these sections:· Title Page (with short title, corresponding author contact information —address, fax, and email—, three to five key words, abbreviations used, and the appropriate journal category. Include 2 brief statements describing the novelty and impact of your paper. Please ensure the fax number is correct and list an alternate number if possible). Mini ReviewsLength should not exceed 4,000 words (3 printed journal pages) plus figures and tables and approximately 50 references. Return to TopPresentation of Forum papersLength should not exceed 4,000 words (3 printed journal pages) plus figures and tables and approximately 50 references. Return to TopLetters to the EditorLetters should begin with a title page (with the heading Letter to the Editor and corresponding author contact information—address, fax, and email). Length should not exceed 2,500 words. Return to TopShort ReportsShort Reports should begin with a title page (with the heading Short Report and corresponding author contact information—address, fax, and email). Length should not exceed 4,000 words.General Elements of ManuscriptsSponsorship and Funding/Financial DisclosureThe Acknowledgments section is an appropriate place to recognize coworkers, indicate funding sources, and disclose information about affiliations and potential conflicts of interest (for example, commercial affiliations, patent-licensing arrangements). The International Journal of Cancer subscribes to the guidelines published by Davidoff et al. in the New England Journal of Medicine 1 and to the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals. 2 Authors must state all their sources of funding and any other financial and personal relationships that might bias their work. If the research reported in the manuscript has received partial or complete funding from commercial sponsors, the authors must also include a statement to that effect. The Editors reserve the right not to consider a manuscript if a sponsor has asserted control over the authors' right to publish their research results. Therefore, if the authors have a potential financial or personal conflict of interest, they must submit the Conflict of Interest form.Return to Top Gene NamesPlease mark all gene names in italics. Only the gene names should be written in italics, to distinguish them from gene products, gene segments, clusters, families, complexes, or groups. Authors should only use the official gene name as assigned by the respective gene nomenclature committee.Return to Top ReferencesThe Journal introduces a new reference style. If you use the program EndNote, please note that you can download the IJC reference style sheet from the Wiley Interscience page. Please see examples below.References are listed in a separate reference section immediately following the text. All references must be verified by the corresponding author who submits the manuscript to International Journal of Cancer. Follow the style of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" 2 for reference format and Index Medicus 3 for standard journal abbreviations (please see examples below). Number references sequentially in the order cited in the text; do not alphabetize. A reference cited only in a table or figure is numbered in the sequence established by the first mention in the text of the table or figure containing the reference. Reference to a personal communication or to a manuscript categorized as in preparation or submitted for publication is discouraged. However, if such a reference is essential and refers to a written communication, the source is cited parenthetically in the text (not in the reference section) with the comment "unpublished data" or "personal communication." Written permission from the source that is cited must be sent to the Editorial Office. Reference to a paper accepted but not yet published is listed in the reference section as "in press." "In press" references must be updated by the authors as soon as publication data is available. Journal references shall include the specified information listed in the following order: authors, article title and subtitle, journal abbreviation, year, volume number in Arabic numerals, and inclusive pages:
Book references are listed as follows: authors, title, edition (if other than the first), volume (if more than one), city, publisher, year, pages: Sobin LH, Wittekind C, eds. TNM classification of malignant tumors, 5th ed. New York: Wiley-Liss, 1997. 227p When referencing a book chapter, the order changes as follows: authors of the chapter, title of the chapter, "In:" editors/authors of the book, title of the book, edition (if there are more than one), volume (if there are more than one), city, publisher, year, and inclusive pages of the chapter: Luketich JD, Ginsberg RJ. Diagnosis and staging of lung cancer. In: Johnson BE, Johnson DH. Lung cancer. New York: Wiley-Liss, Inc., 1995:161-73. FiguresAuthors should upload high-quality graphic data for figures. For use in the peer review process, the Editorial office can use PPT, GIF, TIF, JPG, and EPS files. Figures may be submitted in these formats. However, the preferred format is tif or eps, which would be required when the paper is accepted.Electronic Supplementary MaterialMaterial that is not suitable for print publication such as very long tables, database information, etc. can be published online as electronic supplementary material. The final decision to do so, however, lies with the Editors. Please submit camera-ready files for this material as it will not be edited or altered in any way by the publisher.Return to Top Editorial ProcessAll papers are assessed initially by the editors. A selection of papers is then sent for external review to experts in the field. When a decision is reached, a decision letter is sent to the authors by email and the decision is posted on the IJC website (http://mc.manuscriptcentral.com/ijc-wiley), where the comments of the referees can also be viewed. Decision letters for papers not sent for review are also sent by email and the decision also posted. To aid in the peer review, we invite authors to suggest potential reviewers of their paper (including address, fax, and email) in the cover letter, on the submission form or in the online submission procedure. The authors also have the option of naming nonpreferred reviewers. Receipt of a manuscript is acknowledged by email.We remind you that in submitting to International Journal of Cancer you agree that your work is original in presentation and content and that the work has neither been published elsewhere — including being posted on any site on the Internet — nor is simultaneously under submission as a complete paper with another journal. Return to Top Submission ProcedureNew SubmissionsPlease submit all new manuscripts online. Individual files should be uploaded for the text (doc or rtf format), tables (doc or rtf for text or tif or eps for graphics) and figures (tif or eps). You do not need to mail any copies. Launch your web browser and go to http://mc.manuscriptcentral.com/ijc-wiley/. Check for an existing account. If you are submitting for the first time, create a new account. Follow the step-by-step instructions. Please note that the paper should be submitted by or on behalf of the corresponding author so that he/she receives all correspondence from the system.At the end of a successful submission, a confirmation screen with a manuscript number will appear and you will receive an e-mail confirming that the manuscript has been received by the journal. If this does not happen, please check your submission and/or contact technical support at edsupport@wiley.com. Exceptionally, manuscripts can be submitted by express mail or post, by email, or by ftp. Please contact the Editorial Office by email regarding specific requirements. Required Documents for New SubmissionsFor new submissions we require the following documents, which can be uploaded as a pdf file to the web or sent to us by fax or mail. The required forms can be found on our website ( http://www3.interscience.wiley.com/cgi-bin/jabout/29331/ForAuthors.html ). They can be submitted by post, fax, email, or uploaded to the website along with the manuscript.Cover Letter. Please introduce your work in a cover letter in which you address the following questions:
Submission Form. The Journal requires written consent of all authors upon submission and again upon acceptance, verifying agreement with content and presentation, and knowledge of submission to International Journal of Cancer Financial Disclosure/Conflict of Interest Form. Authors are requested to provide a statement concerning any commercial sponsorship, commercial affiliations, stock/equity interests, or patent licenses of potential financial disclosure with the work presented in the submitted paper. Each author who has NOT checked the box on the submission form indicating that he/she has no conflict of interest must submit the Conflict of Interest form. The paper cannot be processed until these forms are complete.. See section on Sponsorship and Funding/Financial Disclosure . Copyright Transfer Agreement (signed by at least one author) Letter of Permission. Permission is required from the appropriate investigators when "personal communication" or "unpublished data" is cited in the manuscript or from the publisher if previously published material has been used in the manuscript. Return to Top Submission of Revised ManuscriptsIf you have been invited to submit a revised manuscript, please submit it online via your author center. Instructions can be found there:Enter your point-by-point responses to the associate editor and reviewers separately at the “View and Respond” button. Upload two versions of the revised paper, one clean copy and another with all changes underlined or marked. Please also reupload figures and tables. Editorial DecisionsRejected PapersPapers may be rejected either based on the opinions of the Editors or based on the comments of external reviewers. Papers not reaching a high enough level of priority or not fitting within the scope of the Journal will be returned to authors without detailed comments. Only papers of high priority will be considered. We will keep any glossy figures of rejected manuscripts for 3 months and will return them upon request.Return to Top Revisions RequestedIf the Editors and the reviewers respond positively to a paper and are interested in considering it further after additional work is included, authors will be invited to resubmit the manuscript to IJC. A decision letter will be sent by email containing the comments of the referees and/or Editors. We ask that revisions are made within 3 months. Any questions concerning the requested changes/additional work should be addressed to the Editors by fax or email before submission of the revised paper. Revised manuscripts may be returned to the original reviewers for reassessment. Therefore, the review process of the revised manuscript may take over a month in some cases. The Editors maintain the option to reject a paper in a second or third round of revision if the specific concerns have not been met or if the paper still does not meet a high enough level of priority. Please always include the manuscript number in any correspondence and the submission documents.Return to Top Accepted PapersWhen a manuscript is accepted for publication by the editors, it is sent to the publisher (Wiley-Liss, Inc., Hoboken, NJ) for typesetting, copyediting and printing. An electronic proof of the typeset and copyedited version will be sent to the author for approval. We ask that you report any changes immediately to the publisher. Manuscripts will be held in the Heidelberg editorial office if outstanding materials are required (submission form for final, accepted version of the paper, conflict of interest form, and copyright transfer agreement if this has not been submitted previously). Electronic proofs may take approximately 6 weeks to generate. The publisher, Wiley-Liss, Inc., may be contacted with questions about proofs. See contact information.Return to Top Publication and Technical InformationGuidelines for Final Version of Accepted PapersThe final versions of accepted papers (text, tables and figures) should be sent to the editorial office in electronic form, preferably as email attachments to intjcanc@dkfz.de.TextSoftware and Format. The latest version of Microsoft Word or Rich Text Format (RTF) is preferred, although manuscripts prepared with other operating systems and software may be accommodated. Do not use desktop publishing software such as Aldus PageMaker or Quark XPress. If you prepared your manuscript with one of these programs, including EndNote, please export the text to a word processing format. Return to Top FiguresAuthors should upload high-quality graphic data for figures. The required format is TIFF or EPS.All color figures will be reproduced in full color in the online edition of the journal at no cost to authors. Authors are requested to pay the cost of reproducing color figures in print. When necessary to convey essential scientific information authors are encouraged to submit color illustrations. For best reproduction, bright, clear colors should be used. Dark colors against a dark background do not reproduce well; please place your color images against a white background wherever possible. To ensure that your digital graphics are suitable for print purposes, please go to RapidInspector™ at http://rapidinspector.cadmus.com/zwi/index.jsp . This free, stand-alone software application will help you to inspect and verify illustrations right on your computer.
ChargesPage ChargesThere is no fee for the first 8 pages of an article. A fee of US$150.00 for each page beyond the first 8 will be charged. (To calculate the number of printed pages your manuscript will become, count the number of text pages, allowing a page for each table and figure, and divide the total by 3. This gives a rough estimate.)Return to Top Color ChargesPlease be aware that the cost of color printing will be incurred by the author. The color fee is US$500 per page.Return to Top Notice of Wiley’s Compliance with NIH Grants and Contracts PolicyRecently, the National Institutes of Health (NIH) has requested that its grantees submit copies of manuscripts upon their acceptance for publication to PubMedCentral (PMC), a repository housed within the National Library of Medicine. On behalf of our authors who are also NIH grantees, Wiley will deposit in PMC at the same time that the article is published in our journal the peer-reviewed version of the author's manuscript. Wiley will stipulate that the manuscript may be available for "public access" in PMC 12 months after the date of publication. By assuming this responsibility, Wiley will ensure that authors are in compliance with the NIH request, as well as make certain the appropriate version of the manuscript is deposited. When an NIH grant is mentioned in the Acknowledgments or any other section of a manuscript, Wiley will assume that the author wants the manuscript deposited into PMC, unless the author states otherwise. The author can communicate this via email, or a note in the manuscript. The version of the manuscript that Wiley sends to PMC will be the accepted version, i.e. the version that the journal's Editor-in-Chief sends to Wiley for publication. Wiley will notify the author when the manuscript has been sent to PMC. Because Wiley is taking the responsibility for sending the manuscripts to PMC, in order to ensure an orderly process, authors should not deposit Wiley articles to PMC themselves. Authors should not make corrections to their Wiley-deposited manuscripts in PMC. Wiley reserves the right to change or rescind this policy. For further information, please get in touch with your editorial contact at Wiley, or see the NIH Policy on Public Access, located at: http://www.nih.gov/about/publicaccess/ . Contact InformationWe invite inquiries to the editorial office at any time during the editorial process. For all matters concerning presubmission, editorial policies and procedures, and general production matters, please contact the Heidelberg editorial office. Specific questions regarding your proofs and copy editing of your manuscript can be handled by the publisher, Wiley-Liss, Inc., in Hoboken. You can reach the publisher's production department at ijcprod@wiley.comFootnotes | 
|
 | |||||||||||||||||||
|
|
|||||||||||||||||||||
 | EBM Guidelines |
(Evidence-Based Medicine) The key source of practical information for primary care with the most extensive collection of concise treatment recommendations more | |
 | Current Protocols in Cell Biology |
Updated every three months, an essential reference for methods for researchers who study the cell - its structure, organization, behavior, and functions. Now available via individual online subscription! | |
| Current Protocols in Toxicology |
A "best-practices" collection of lab protocols for accurate, efficient assessments of toxicity in whole organisms, organs and tissues, cells, and biochemical pathways. Now available via individual online subscription! | |